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Bacteroides fragilis is one of the most important 
causes of intraabdominal infections and bacteremia 
which might be fatal if not properly treated (Wexler 
et al., 2007). Carbapenems are generally used for the 
treatment of anaerobic infections, but production of 
carbapenemases by Bacteroides spp. renders these anti-
microbials ineffective (Sóki et al., 2000). An important 
mechanism of carbapenem resistance in Bacteroides 
spp. is the acquisition of the cfiA gene encoding a met-
allo-beta-lactamase enzyme that is able to hydrolyse 
carbapenemes. If present, the cfiA gene may or may 
not cause clinical resistance depending on expression 
level of enzyme, or else the gene may stay completely 
silent (Ang et al., 2007). The molecular detection of the 
cfiA gene by itself is not indicative of clinical carbape-
nem resistance; supplementary phenotypic tests are 
needed to determine the carbapenem susceptibility 
of clinical Bacteroides isolates, such as performance 
of the minimal inhibitory concentration (MIC) testing 
for carbapenems.
Laboratory detection of the carbapenemase genes 
is challenging, moreover carbapenemase-producing 
bacteria are spreading throughout the world (Cantón 
et al., 2012). Many strains have carbapenem MICs in 
the susceptible range, and different phenotypic meth-
ods designed to detect such strains lack specificity and 
sensitivity such as the modified Hodge test, and com-
bined disk tests with different inhibitors (Nordmann 
et al., 2012). Detection of carbapenemase genes and 
demonstration of the ability of a strain to hydrolyze 
carbapenems still remain the gold standard methods 
for identification of carbapenemase-producing isolates 
(Poirel et al., 2013). The recently published Carba NP 
test is described as a biochemical method based on 
imipenem hydrolysis (Nordmann et al., 2012). Without 
any specialized equipment, the CARBA NP test detects 
the pH change by colorimetric pH indicator caused by 
the breakdown of imipenem in a solution containing 
lysed test bacteria. The test’s specificity and sensitiv-
ity were initially reported as 100% when results were 
compared with those of molecular-based methods, the 
reference standard for identifying carbapenemase genes 
(Nordmann et al., 2012). 
The usefulness of Carba NP test has been demon-
strated for many Gram-negative bacteria, including 
Enterobacteriacae, Acinetobacter spp. and Pseudomonas 
aeruginosa (Nordmann et al., 2012; Dortet et al., 2012; 
Dortet et al., 2014). In this study, our aim was to inves-
tigate the carbapenemase activity in clinical Bacteroides 
spp. isolates by Carba NP test and compare the results 
obtained from the Carba NP test with phenotypic (car-
bapenem MICs) and genotypic (presence or absence 
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A b s t r a c t
We evaluated the usefulness of the Carba NP test for rapid detection of carbapenemase activity in Bacteroides spp. The minimum inhibitory 
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of the cfiA gene), and thus assess the usefulness of the 
Carba NP test for the detection of carbapenemase activ-
ity in Bacterodies spp. 
A total of 27 clinical Bacteroides spp. isolates col-
lected between 2011 and 2016 were included in this 
study. The distribution of strains to isolation sites is 
presented in Table I. All isolates were stored at −80°C 
in cryopreservation vials (Salubris, Turkey). Frozen 
stock cultures were used to inoculate subcultures which 
were routinely grown on Schaedler agar (bioMérieux, 
France) and incubated at 35–37°C in anaerobe pouch 
system (GasPak™ EZ Anaerobe Pouch System, Becton 
Dickinson, USA). For species identification matrix-
assisted laser desorption/ionization time-of-flight mass 
spectrometry (MALDI-TOF MS) (Bruker Daltonics, 
Germany) was used.
The susceptibility of the Bacteroides spp. to imipenem 
(IMP) was determined by gradient strips according to 
the manufacturer’s recommendations. In the current 
study, bacterial suspension matched to 1  McFarland 
standard was prepared from fresh colonies and inocu-
lated onto Brucella agar with 5% sheep blood supple-
mented with hemin and vitamin K1 (Salubris, Turkey), 
then an IMP gradient strip was placed onto agar sur-
face for each isolate (Oxoid™ M.I.C.Evaluator™ Strips, 
Thermo Scientific, UK). The plates were incubated in 
anaerobe pouch system at 35–37°C for 24–48 hours. 
B. fragilis ATCC 25285 was used as a reference strain. 
The clinical breakpoints recommended by the Euro-
pean Committee on Antimicrobial Susceptibility 
Testing (EUCAST) were used to interpret the results 
(EUCAST, 2016).
Bacterial DNA was extracted by a commercial kit 
(High Pure PCR Template Preparation Kit, Roche, 
Germany). The carbapenemase coding gene cfiA was 
amplified by polymerase chain reaction (PCR) with the 
following primers: cfiA-RT1 (5’-AATCGAAGGA TGGG 
GTATGG-3’) and cfiA-RT2 (5’-CGGTCGGTG AATCG- 
GTGAAT-3’) which amplify 300 bp of the 750 bp cfiA 
gene (Sóki et al., 2013). A B. fragilis strain with previ-
ously documented cfiA positivity was used as a posi-
tive control in PCR studies (Toprak et al., 2012).The 
PCR cycles were as follows: 2 minutes at 94°C, 35 cycles 
(45 seconds at 94°C, 45 seconds at 51°C, 45 seconds at 
72°C) and 2 minutes at 72°C. For the visualisation of 
PCR products, 2% agarose gel was used which were 
stained with SYBR gold and monitored using ORTE 
device (Salubris Technica, Istanbul, Turkey). 
Carba NP test was performed according to CLSI 
recommendations (CLSI, 2016). For each strain two 
microcentrifuge tubes (1.5 ml) labeled as “a” and “b” 
were used. The bacterial colonies grown on Schaedler 
agar were collected after 24 hours and a loopful of bac-
teria (approximately 10 µl) were added into 100 µl of 
bacterial protein extraction reagent (B-PERII, Thermo 
Scientific, Pierce) and stirred for 5 seconds. From the 
solutions A (containing zinc sulphate and phenol red, 
pH: 7.8 ± 0.1) and B (containing solution A and 6 mg/ml 
imipenem), 100 µl solution was added to a, and b tubes, 
respectively, and then incubated at 35 ± 2°C for up to 
two hours. The results were interpreted according to 
the color changes of the tubes. The carbapenemase-pro-
ducing B. fragilis strain TAL 2480 was used as positive 
control and B. fragilis ATCC 25285 was used as negative 
control. The microcentrifuge tubes which contain only 
bacterial protein extraction reagents were prepared as 
reagent control. When imipenem was hydrolysed, the 
color of the tube’s content turned from red to orange 
or yellow which was interpreted as a positive Carba NP 
test, whereas tubes containing bacterial extracts of iso-
lates with no carbapenemase activity remained red. The 
color changed from red to yellow as early as 30 minutes 
after incubation with B. fragilis TAL 2480 (Fig. 1).
Imipenem MIC values determined by gradient 
strips ranged from 0.03 to ≥ 32 mg/l among study iso-
lates. Majority (24 out of 27; 88.9%) of the strains were 
found susceptible to imipenem (MIC ≤ 2 mg/l) with 
EUCAST breakpoints, one strain showed intermediate 
susceptibility (MIC = 4 mg/l) and two of the strains were 
found resistant to imipenem (MIC ≥ 16 mg/l). The cfiA 
Blood 8 1 1 2 12
Abdominal infection 4 1 2 – 7
Rectal, anal, perirectal abscess 4 – – – 4
Wound 1 1 – – 2
Abscess 1 – – – 1
Urine – 1 – – 1
Total (%) 18 (66.7) 4 (14.8) 3 (11.1) 2 (7.4) 27
Table I
Distribution of the clinical Bacteroides spp. isolates and sources.
Source
Number of isolates
Total
B. fragilis B. vulgatus B. thetaiotao-micron B. caccae
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gene was detected in three isolates (11.1%), all B. fragilis 
blood isolates with imipenem MIC ≥ 4 μg/ml. A cor-
relation between imipenem MIC being ≥ 4 μg/ml and 
cfiA gene positivity was observed for the tested Bacte-
roides sp. isolates. Carba NP test results were obtained 
in 2 hours in clinical isolates and in 30 minutes for the 
reference strain. The two clinical strains with imipenem 
MIC ≥ 32 mg/l and the reference cfiA positive strain 
were tested positive in the Carba NP test, however the 
imipenem intermediate (MIC = 4 mg/l), cfiA positive 
strain was found negative (Table II). 
In the present study, we aimed to evaluate the 
applicability of the Carba NP test, which was origi-
nally developed for Enterobacteriaceae, to investigate 
the cfiA-mediated carbapenemase production in Bac-
teroides spp. The cfiA gene was investigated in a col-
lection of clinical Bacteroides sp. isolates (n = 27) and 
we found three (11.1%) cfiA positive B. fragilis isolates. 
Carba NP test positive 0 0 2
cfiA positive 0 1 2
Total 24 1 2
Table II
Correlation of cfiA gene presence and Carba NP test positivity
with imipenem MICs in clinical Bacteroides spp. isolates (n = 27).
*According to EUCAST breakpoints,  S = susceptible,  I = intermediate,  R = resistant
Imipenem Susceptibility (Imipenem MIC)
S*
(MIC ≤ 2 mg/l)
I*
(MIC = 4 – 8 mg/l)
R*
(MIC ≥ 16 mg/l)
Fig. 2. The PCR amplification results for the cfiA gene in clinical Bacteroides spp. isolates.
Lanes 1, 3 and 4 are clinical B. fragilis isolates demonstrating the presence of the cfiA gene, lanes 2, 5–10 
are clinical Bacteroides spp. lacking the cfia gene, lane 11 is negative control (water), lane 12 is a cfiA posi-
tive B. fragilis strain used as positive control. Molecular sizes in base pair (bp) are indicated at the left. 
(M: Molecular mass standard) This PCR assay was used to amplify a 302 bp fragment of the cfiA gene.
Fig. 1. Interpretation of the Carba NP test results: B. fragilis ATCC 25285 with no carbapene-
mase activity (left) and carbapenemase-producing B. fragilis strain TAL 2480 (right).
The tubes denoted as “a” contain solution A + bacterial lysate, tubes “b” contain solution B (solution A + 
imipenem) + bacterial lysate. If acidification occurs as a result of hydrolysis of imipenem, the pH indicator 
(phenol red) causes a color change from red to yellow in tube b.
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The Carba NP test yielded positive results for two of the 
cfiA positive isolates both having imipenem MICs of 
≥ 16 mg/l but the test gave negative results for the cfiA 
positive isolate with imipenem MIC of 4 mg/l. No posi-
tive Carba NP test results were obtained in imipenem 
susceptible (MIC ≤ 2 mg/l) and cfiA negative isolates. 
Our results with the limited isolate collection suggest 
that Carba NP test can also be used for Bacteroides spp. 
to have preliminary information on carbapenem sus-
ceptibility. The positive results with the Carba NP test 
are very likely to be related with high carbapenem MIC 
values which might be taken as a warning for treatment 
failure if carbapenems are used.
Bacteroides spp. are the predominant members 
of the human intestinal microbiota and constitute 
approximately 30% of the total colonic bacteria. They 
are also among the most commonly isolated anaerobic 
bacteria from clinical specimens. The B. fragilis group 
is of special medical importance since they are often 
involved in polymicrobial infections, bear the potential 
to express β-lactamases and are associated with a high 
mortality when causing bloodstream infections (Wexler 
et al., 2007). A French multicenter study determined 
the role of anaerobe bacteria in the aetiology of all bac-
teremias as 0.5% to 9%, of which 60% being caused 
by Bacteroides spp. (Zahar et al., 2005). These factors 
emphasize the importance of identification and rapid 
antimicrobial susceptibility testing for clinical Bacte-
roides spp. isolates for the administration of appropriate 
antibiotic therapy to achieve optimal outcomes. Access 
to rapid susceptibility results is important in the case 
of infections due to Bacteroides spp. since the suscep-
tibility of these bacteria cannot be predicted due to the 
ability of the organism to acquire resistance mecha-
nisms. The B. fragilis group are uniformly resistant to 
penicillin and first generation cephalosporins which 
leaves limited number of alternatives such as metro-
nidazole, imipenem, piperacillin-tazobactam, moxi-
floxacin and clindamycin with reported resistance rates 
of < 1%, 1.2%, 3.1%, 13.6%, and 32.4%, respectively 
(Nagy et al., 2011). A Europe-wide study showed that 
imipenem retains its activity against B. fragilis isolates, 
but the percentage of isolates with reduced susceptibil-
ity (MIC: ≥ 4 mg/L) are steadily increasing (Nagy et al., 
2011). Carbapenem resistance in B. fragilis is most com-
monly related to the acquisition of cfiA gene which – if 
expressed at high levels due to acquisition of an inser-
tion sequence upstream of the gene – can lead to high-
level carbapenem resistance (Thompson et al., 1990; 
Edwards et al., 2000). The frequency of cfiA positivity 
in Bacteroides spp. has been reported to be as high as 
27% in a Turkish study (Toprak et al., 2012), raising 
concern as an emerging resistance trait that may limit 
the empirical use of carbapenems in infections due 
to Bacteroides spp. 
Our study findings revealed the rate of cfiA positiv-
ity as 11.1% in a small collection of clinical Bacteroides 
sp. isolates. This is in concordance with previously pub-
lished literature in which rates ranging between 0 and 
13% was observed for a collection of 161 B. fragilis group 
strains isolated from nine different European countries 
(Eitel et al., 2013). The high rate of 27% cfiA positivity 
reported from Istanbul, Turkey in this study, might be 
related with the institutional spread of a resistant clone.
We also had the opportunity to test other Bacte-
riodes species by including a few B. thetaiotaomicron, 
B. caccae and B. vulgatus isolates, however the study col-
lection mostly consisted of clinical B. fragilis isolates. 
The total number of isolates tested is relatively low for 
a validation study, but the collection included cfiA gene 
positive and negative isolates with varying imipenem 
MIC values that enabled us to investigate the perfor-
mance of the test. Additionally, the high concordance 
observed between the phenotypic and genotypic test 
results further supports the applicability of CARBA NP 
test in Bacteroides spp.
In our study, we demonstrated the usefulness of 
the recently described Carba NP test to detect carbap-
enemase activity in clinical Bacteroides spp. isolates. 
Although further studies are needed, with our prelimi-
nary results, we can suggest that the Carba NP test holds 
the potential to be used as a rapid phenotypic carbapen-
emase detection test for Bacteroides species. The rapid 
detection of carbapenemase activity in Bacteroides spp. 
might provide early insight into susceptibility of the 
organism before the final results of the conventional 
antimicrobial susceptibility are obtained, and thus serve 
as an important tool to manage antimicrobial therapy.
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